Johnson & Johnson adds up to consistency, quality, success
If long-term sustainable wealth creation is your goal, look no further than Johnson & Johnson (NYSE: JNJ) as a candidate for your portfolio. It performs strongly year in and year out, regardless of the overall economy.
Johnson & Johnson features three main operating segments: medical devices and diagnostics, pharmaceutical and consumer – and controls more than 275 operating companies in all. Its medical devices and diagnostics segment is the largest medical technology business in the world, and a relatively rapid grower.
The consumer segment contains several world-class brands found in nearly every U.S. household – think Band-Aid, Listerine, Tylenol, and the company’s namesake baby care products. Its pharmaceutical business is less steady, but solid.
J&J generates approximately 70 percent of its revenue from products that hold the No. 1 or No. 2 global market positions. It has delivered 29 consecutive years of adjusted earnings increases, and earlier this year increased its dividend for the 50th year in a row. (It recently yielded 3 percent.) With a fortress-like balance sheet, J&J is one of only four nonfinancial, U.S.-based companies to hold the triple-A credit rating from Standard & Poor’s.
Add it all up, and what you’re left with is a hugely profitable, remarkably consistent company. (The Motley Fool’s newsletters have recommended it.)
Ask the Fool
Q: What does “Nasdaq” refer to? – B.R., Scranton, Pa.
A: Created in 1971 as the National Association of Securities Dealers Automated Quotations (NASDAQ), it’s now the largest electronic stock market in America, where shares of about 3,200 companies are traded. It boasts more companies and, on average, more trades per day than any other U.S. market. Learn more at nasdaq.com.
My smartest investment
I retired in 1975, and up to that point I’d lost money in the stock market by taking the advice of brokers. I learned to use Value Line reports to pick stocks, and as a result, my stocks have soared in value. My wife and I have traveled around the world and attended six Olympic Games. – R.W., Lancaster, Pa.
The Fool responds: Value Line has been around since 1931 and has both fans and foes. At ValueLine.com, you can read about how stocks that are top-ranked per the Value Line system have soundly beaten the market over time.
Detractors will point out that trading costs and taxes are ignored in such calculations, and that the portfolio rejiggering required to hold only top-rated stocks would generate significant commission charges and short-term capital gains hits. The flagship Value Line Fund (VLIFX), launched in 1950, has underperformed the market over the past 10 and 15 years.
Still, you don’t have to blindly follow Value Line – you might just learn about companies from its reports and then make your own decisions. You seem to have done just that, with solid results.